What do oncologists say about chemotherapy at the very end of life? Results from a semiqualitative survey

Deepti Behl, Aminah Jatoi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aim: This study elicited oncologists' insights into published statistics that 20% of cancer patients receive chemotherapy within 2 weeks of death and that the median survival between chemotherapy administration and death is 37 days. Subjects and methods: A semiqualitative survey was developed to enable respondents to provide anonymous, write-in comments on the statistics above. This survey was sent electronically on two separate occasions to oncologists in the upper midwestern United States. Qualitative methods were used to analyze data. Results: A total of 422 oncology health-care providers were sent the survey, and 61 responded. Nine themes emerged: 1) these decisions are strongly patient-driven; 2) newer agents are driving the decision to continue with cancer treatment; 3) financial incentives on the part of the medical community explain these high rates; 4) health-care reform is necessary; 5) even a small chance of patient benefit justifies this practice; 6) this practice is detrimental to patients because it precludes the initiation of hospice services; 7) others may be prescribing in this manner, but "not us"; 8) these issues are complicated, revolve around society values, and the oncologist alone cannot claim responsibility for such high rates of chemotherapy administration; and 9) there exist barriers to end-of-life discussions. Conclusion: Many oncologists are in fact reluctant to prescribe chemotherapy at the end of life, and the complexity of this topic underscores the potential for oncologists and palliative care providers to collaborate in an effort to provide cancer patients the best care at the very end of life.

Original languageEnglish (US)
Pages (from-to)831-835
Number of pages5
JournalJournal of Palliative Medicine
Volume13
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Drug Therapy
Midwestern United States
Neoplasms
Hospices
Health Care Reform
Palliative Care
Health Personnel
Motivation
Patient Care
Surveys and Questionnaires
Oncologists
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Anesthesiology and Pain Medicine
  • Nursing(all)

Cite this

What do oncologists say about chemotherapy at the very end of life? Results from a semiqualitative survey. / Behl, Deepti; Jatoi, Aminah.

In: Journal of Palliative Medicine, Vol. 13, No. 7, 01.07.2010, p. 831-835.

Research output: Contribution to journalArticle

@article{b58373bd1aef4c63b812880435087a09,
title = "What do oncologists say about chemotherapy at the very end of life? Results from a semiqualitative survey",
abstract = "Aim: This study elicited oncologists' insights into published statistics that 20{\%} of cancer patients receive chemotherapy within 2 weeks of death and that the median survival between chemotherapy administration and death is 37 days. Subjects and methods: A semiqualitative survey was developed to enable respondents to provide anonymous, write-in comments on the statistics above. This survey was sent electronically on two separate occasions to oncologists in the upper midwestern United States. Qualitative methods were used to analyze data. Results: A total of 422 oncology health-care providers were sent the survey, and 61 responded. Nine themes emerged: 1) these decisions are strongly patient-driven; 2) newer agents are driving the decision to continue with cancer treatment; 3) financial incentives on the part of the medical community explain these high rates; 4) health-care reform is necessary; 5) even a small chance of patient benefit justifies this practice; 6) this practice is detrimental to patients because it precludes the initiation of hospice services; 7) others may be prescribing in this manner, but {"}not us{"}; 8) these issues are complicated, revolve around society values, and the oncologist alone cannot claim responsibility for such high rates of chemotherapy administration; and 9) there exist barriers to end-of-life discussions. Conclusion: Many oncologists are in fact reluctant to prescribe chemotherapy at the end of life, and the complexity of this topic underscores the potential for oncologists and palliative care providers to collaborate in an effort to provide cancer patients the best care at the very end of life.",
author = "Deepti Behl and Aminah Jatoi",
year = "2010",
month = "7",
day = "1",
doi = "10.1089/jpm.2009.0414",
language = "English (US)",
volume = "13",
pages = "831--835",
journal = "Journal of Palliative Medicine",
issn = "1096-6218",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - What do oncologists say about chemotherapy at the very end of life? Results from a semiqualitative survey

AU - Behl, Deepti

AU - Jatoi, Aminah

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Aim: This study elicited oncologists' insights into published statistics that 20% of cancer patients receive chemotherapy within 2 weeks of death and that the median survival between chemotherapy administration and death is 37 days. Subjects and methods: A semiqualitative survey was developed to enable respondents to provide anonymous, write-in comments on the statistics above. This survey was sent electronically on two separate occasions to oncologists in the upper midwestern United States. Qualitative methods were used to analyze data. Results: A total of 422 oncology health-care providers were sent the survey, and 61 responded. Nine themes emerged: 1) these decisions are strongly patient-driven; 2) newer agents are driving the decision to continue with cancer treatment; 3) financial incentives on the part of the medical community explain these high rates; 4) health-care reform is necessary; 5) even a small chance of patient benefit justifies this practice; 6) this practice is detrimental to patients because it precludes the initiation of hospice services; 7) others may be prescribing in this manner, but "not us"; 8) these issues are complicated, revolve around society values, and the oncologist alone cannot claim responsibility for such high rates of chemotherapy administration; and 9) there exist barriers to end-of-life discussions. Conclusion: Many oncologists are in fact reluctant to prescribe chemotherapy at the end of life, and the complexity of this topic underscores the potential for oncologists and palliative care providers to collaborate in an effort to provide cancer patients the best care at the very end of life.

AB - Aim: This study elicited oncologists' insights into published statistics that 20% of cancer patients receive chemotherapy within 2 weeks of death and that the median survival between chemotherapy administration and death is 37 days. Subjects and methods: A semiqualitative survey was developed to enable respondents to provide anonymous, write-in comments on the statistics above. This survey was sent electronically on two separate occasions to oncologists in the upper midwestern United States. Qualitative methods were used to analyze data. Results: A total of 422 oncology health-care providers were sent the survey, and 61 responded. Nine themes emerged: 1) these decisions are strongly patient-driven; 2) newer agents are driving the decision to continue with cancer treatment; 3) financial incentives on the part of the medical community explain these high rates; 4) health-care reform is necessary; 5) even a small chance of patient benefit justifies this practice; 6) this practice is detrimental to patients because it precludes the initiation of hospice services; 7) others may be prescribing in this manner, but "not us"; 8) these issues are complicated, revolve around society values, and the oncologist alone cannot claim responsibility for such high rates of chemotherapy administration; and 9) there exist barriers to end-of-life discussions. Conclusion: Many oncologists are in fact reluctant to prescribe chemotherapy at the end of life, and the complexity of this topic underscores the potential for oncologists and palliative care providers to collaborate in an effort to provide cancer patients the best care at the very end of life.

UR - http://www.scopus.com/inward/record.url?scp=77954931175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954931175&partnerID=8YFLogxK

U2 - 10.1089/jpm.2009.0414

DO - 10.1089/jpm.2009.0414

M3 - Article

C2 - 20636153

AN - SCOPUS:77954931175

VL - 13

SP - 831

EP - 835

JO - Journal of Palliative Medicine

JF - Journal of Palliative Medicine

SN - 1096-6218

IS - 7

ER -